Definitive chemoradiation for oesophageal cancer--a standard of care in patients with non-metastatic oesophageal cancer
Definitive chemoradiation for oesophageal cancer--a standard of care in patients with non-metastatic oesophageal cancer
Aims: a retrospective analysis was carried out of 291 cases of oesophageal cancer treated with definitive chemoradiotherapy (dCRT) at a single UK cancer centre between 1995 and 2009. Our protocol consisted of two cycles of neoadjuvant platinum-based chemotherapy followed by two further cycles given concurrently with 50 Gy of external beam radiotherapy delivered in 25 fractions over 5 weeks.
Materials and methods: demographic, patient and outcome data were recorded prospectively through an electronic health record and retrospectively analysed, using appropriate statistical tools.
Results: data on 266 patients were available for analysis. The median age was 66.6 years, 53% were adenocarcinomas. dCRT was used instead of surgery because of age/co-morbidity in 44% and disease extent in 39%. Ninety-three per cent of patients completed treatment according to protocol. Grade 3 and 4 toxicities were seen in 42 and 7%, respectively. Median survival was 20.6 months; 2, 3 and 5 year survival rates were 43.6, 32.9 and 19.5%, respectively. Advanced disease was associated with a worse outcome. Shorter disease length was associated with a better median survival, but some patients with disease >10 cm had long-term disease control. The effect of other patient- and disease-related factors was also analysed.
Conclusion: we present data showing that dCRT is well tolerated and should be considered as an alternative to surgery for all patients with locally advanced oesophageal cancer, not only those with co-morbidity. Furthermore, the benefits of dCRT are not confined to carcinomas with squamous histology.
182-188
Gwynne, S.
0cbce6d8-328d-430e-9f5e-a5885deedac8
Hurt, C.
bf8b37a0-8f08-4b47-b3f3-6fc65f7ab87f
Evans, M.
0f6f0051-a1c3-47d2-9533-566c6a542e8e
Holden, C.
99da8ea9-5b81-4840-94f2-cebd6ad214ac
Vout, L.
654f0715-b987-4a73-aa0d-9e016ba2dd36
Crosby, T.
82fd6364-ad6d-4e24-bb81-e1868258c4e6
April 2011
Gwynne, S.
0cbce6d8-328d-430e-9f5e-a5885deedac8
Hurt, C.
bf8b37a0-8f08-4b47-b3f3-6fc65f7ab87f
Evans, M.
0f6f0051-a1c3-47d2-9533-566c6a542e8e
Holden, C.
99da8ea9-5b81-4840-94f2-cebd6ad214ac
Vout, L.
654f0715-b987-4a73-aa0d-9e016ba2dd36
Crosby, T.
82fd6364-ad6d-4e24-bb81-e1868258c4e6
et al.
(2011)
Definitive chemoradiation for oesophageal cancer--a standard of care in patients with non-metastatic oesophageal cancer.
Clinical Oncology, 23 (3), .
(doi:10.1016/j.clon.2010.12.001).
Abstract
Aims: a retrospective analysis was carried out of 291 cases of oesophageal cancer treated with definitive chemoradiotherapy (dCRT) at a single UK cancer centre between 1995 and 2009. Our protocol consisted of two cycles of neoadjuvant platinum-based chemotherapy followed by two further cycles given concurrently with 50 Gy of external beam radiotherapy delivered in 25 fractions over 5 weeks.
Materials and methods: demographic, patient and outcome data were recorded prospectively through an electronic health record and retrospectively analysed, using appropriate statistical tools.
Results: data on 266 patients were available for analysis. The median age was 66.6 years, 53% were adenocarcinomas. dCRT was used instead of surgery because of age/co-morbidity in 44% and disease extent in 39%. Ninety-three per cent of patients completed treatment according to protocol. Grade 3 and 4 toxicities were seen in 42 and 7%, respectively. Median survival was 20.6 months; 2, 3 and 5 year survival rates were 43.6, 32.9 and 19.5%, respectively. Advanced disease was associated with a worse outcome. Shorter disease length was associated with a better median survival, but some patients with disease >10 cm had long-term disease control. The effect of other patient- and disease-related factors was also analysed.
Conclusion: we present data showing that dCRT is well tolerated and should be considered as an alternative to surgery for all patients with locally advanced oesophageal cancer, not only those with co-morbidity. Furthermore, the benefits of dCRT are not confined to carcinomas with squamous histology.
This record has no associated files available for download.
More information
Accepted/In Press date: 29 November 2010
e-pub ahead of print date: 12 January 2011
Published date: April 2011
Identifiers
Local EPrints ID: 488376
URI: http://eprints.soton.ac.uk/id/eprint/488376
ISSN: 0936-6555
PURE UUID: 94af124b-003e-488e-b763-a1e2eed5c92e
Catalogue record
Date deposited: 21 Mar 2024 17:33
Last modified: 23 Mar 2024 03:13
Export record
Altmetrics
Contributors
Author:
S. Gwynne
Author:
C. Hurt
Author:
M. Evans
Author:
C. Holden
Author:
L. Vout
Author:
T. Crosby
Corporate Author: et al.
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics